ABSTRACT
Objective: To analyze the follow-up changes of subjects of anti-cancer clinical trials in our department under the COVID-19 epidemic situation. Methods: The clinical trials were classified. The follow-up status of subjects in our department from February 3 to April 30 and May 6 to 29, 2020 was collected, and the data were input and analyzed by Excel and SPSS 22.0. Results: There were 32 anti-cancer clinical trials in our department. From February 3 to April 30, 2020, 1 049 person times were planned to be followed up, and 658 person times were actually followed up, accounting for 62.73%. The follow-up rate of oral drugs was 93.33%, that of oral drugs combined with non-oral drugs was 87.73%, and that of non-oral drugs was 70.71%. In May 2020, the actual follow-up rate of subjects on site rose to 88.97%, while the number of delayed drug users, the number of external hospital inspectors and the number of non-drug users decreased. Conclusion: The epidemic situation had a great impact on the follow-up of anti-cancer clinical trials in a short time, but did not cause a sustained impact. The establishment of relevant follow-up measures improved the follow-up rate of subjects to some extent. For the affected subject population, further analysis is needed to better guide the follow-up work of subjects under emergency.